Preliminary results from Phase 1b study | 22-Mar-2023 | 07:00 | RNS |
Price Monitoring Extension | 16-Mar-2023 | 14:00 | RNS |
Second Price Monitoring Extn | 16-Mar-2023 | 11:05 | RNS |
Price Monitoring Extension | 16-Mar-2023 | 11:00 | RNS |
No exposure to Silicon Valley Bank | 13-Mar-2023 | 07:00 | RNS |
Clinical trial update | 25-Jan-2023 | 07:00 | RNS |
Grant of Options - Director/PDMR Shareholding | 14-Dec-2022 | 17:08 | RNS |
Half-year Report | 08-Dec-2022 | 07:00 | RNS |
Notice of Half Year Results | 02-Dec-2022 | 07:00 | RNS |
Second Price Monitoring Extn | 30-Nov-2022 | 14:06 | RNS |
Price Monitoring Extension | 30-Nov-2022 | 14:00 | RNS |
Study started of new SFX-01 tablet formulation | 16-Nov-2022 | 07:00 | RNS |
Second Price Monitoring Extn | 21-Oct-2022 | 11:05 | RNS |
Price Monitoring Extension | 21-Oct-2022 | 11:00 | RNS |
Second Price Monitoring Extn | 12-Oct-2022 | 16:41 | RNS |
Currency | UK Pounds |
Share Price | 3.80p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 7.10 |
52 Week Low | 2.85 |
Volume | 100,057 |
Shares Issued | 274.89m |
Market Cap | £10.45m |
RiskGrade | 304 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:35 | 100 @ 3.70p |
15:41 | 7,371 @ 3.75p |
15:08 | 68,007 @ 3.80p |
10:12 | 23,310 @ 3.74p |
08:53 | 1,269 @ 3.80p |
CFO | Richard Moulson |
CEO | Huw Jones |
You are here: research